Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disposition of Eslicarbazepine Acetate and Metabolites in Healthy Volunteers
NCT02281591Phase 1Completed
- Sponsor
- BIAL
- Start
- Jun 2006
- Primary completion
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of eslicarbazepine acetate in epilepsy (4 arms), sponsored by BIAL. Primary endpoints: Maximum Plasma Concentration at Day 11, Time to Maximum Plasma Concentration at Day 11 and 1 more. Started Jun 2006; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02281591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281591.